Related Experiment Video
Updated: Jun 13, 2026
07:20
Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
Published on: January 28, 2014
Molecular biomarkers: a US FDA effort
Huixiao Hong1, Federico Goodsaid, Leming Shi
1Center for Toxicoinformatics, Division of Systems Toxicology, National Center for Toxicological Research, US FDA 3900 NCTR Road, Jefferson, AR, USA. huixiao.hong@fda.hhs.gov
Biomarkers in Medicine
|April 22, 2010
Summary
Molecular biomarkers are increasingly used in FDA-approved drugs for diagnosis and treatment. This review covers their current status, challenges, and future directions in drug development and regulatory review.
Area of Science:
- Biomarkers and Drug Development
- Regulatory Science
- Pharmacogenomics
Background:
- Molecular biomarkers are crucial for disease diagnosis, prognosis, and treatment response assessment.
- The US FDA has seen a significant rise in drug labels including molecular biomarker information over the past decade.
- Pharmaceutical companies are actively developing molecular biomarker programs through various collaborations.
Purpose of the Study:
- To summarize the current landscape of molecular biomarkers in FDA-approved drug products.
- To discuss the challenges and future perspectives in identifying and qualifying molecular biomarkers.
- To highlight relevant FDA programs and research initiatives supporting regulatory review.
Main Methods:
- Review of FDA-approved drug labels for molecular biomarker content.
- Analysis of trends in molecular biomarker utilization in drug development.
- Examination of regulatory pathways and initiatives related to biomarker qualification.
Main Results:
- A notable increase in FDA-approved drugs incorporating molecular biomarkers.
- Widespread adoption of molecular biomarker programs by the pharmaceutical industry.
- Anticipation of further identification and validation of biomarkers for drug approval.
Conclusions:
- Molecular biomarkers are integral to modern drug development and regulatory science.
- Addressing challenges in biomarker identification and qualification is key for future advancements.
- Ongoing FDA programs are vital for supporting the integration of biomarkers in drug approval processes.
Related Concept Videos
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:25Drug Regulation
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
01:13Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...